Iannaccone S T, Russman B S, Browne R H, Buncher C R, White M, Samaha F J
Department of Neurology, University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children, Dallas, USA.
J Child Neurol. 2000 Feb;15(2):97-101. doi: 10.1177/088307380001500207.
Spinal muscular atrophy is a genetic disorder of the motor neurons that causes profound hypotonia, severe weakness, and often fatal restrictive lung disease. Patients with spinal muscular atrophy present a spectrum of disease from the most severe infantile-onset type, called Werdnig-Hoffmann disease (type 1), associated with a mortality rate of up to 90%, to a late-onset mild form (type 3), wherein patients remain independently ambulatory throughout adult life. Although many clinicians agree that patients with spinal muscular atrophy lose motor abilities with age, it is unknown whether progressive weakness occurs in all patients with spinal muscular atrophy. We present here results of the first prospective study of muscle strength in patients with spinal muscular atrophy. There was no loss in muscle strength as determined by a quantitative muscle test during the observation period. However, motor function diminished dramatically in some patients with spinal muscular atrophy. Explanations for this loss of function could not be determined from our data. Decrease in motor function could be caused by factors other than loss of strength. Therefore, it is not clear from our results whether spinal muscular atrophy is a neurodegenerative disease. We conclude that treatment trials in spinal muscular atrophy should be designed with consideration of the natural history of strength and motor function in this disorder.
脊髓性肌萎缩症是一种运动神经元的遗传性疾病,可导致严重的肌张力减退、严重肌无力,且常伴有致命的限制性肺病。脊髓性肌萎缩症患者呈现出一系列疾病表现,从最严重的婴儿期发病类型,即韦尼克 - 霍夫曼病(1型),死亡率高达90%,到迟发性轻度形式(3型),此类患者在成年期仍能独立行走。尽管许多临床医生一致认为脊髓性肌萎缩症患者会随着年龄增长而丧失运动能力,但尚不清楚进行性肌无力是否发生在所有脊髓性肌萎缩症患者中。我们在此展示了对脊髓性肌萎缩症患者肌肉力量进行的首次前瞻性研究结果。在观察期内,通过定量肌肉测试确定肌肉力量没有下降。然而,一些脊髓性肌萎缩症患者的运动功能显著减退。从我们的数据中无法确定这种功能丧失的原因。运动功能下降可能由力量丧失以外的因素引起。因此,从我们的结果尚不清楚脊髓性肌萎缩症是否为神经退行性疾病。我们得出结论,脊髓性肌萎缩症的治疗试验设计应考虑该疾病中力量和运动功能的自然病程。